Protocol: CDISCPILOT01                                                                  Page  1 of 1 
Population: Efficacy 
Table 14-3.09 
ADAS Cog (11) - Change from Baseline to Week 24 in Female Subjects - LOCF 
 
 
[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline 
value as a covariate. 
[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable. 
[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple 
comparisons. 
Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas                  21:05 Monday, June 26, 2006 
 
Placebo 
 (N=46)  
Xanomeline 
 Low Dose 
 (N=47)  
Xanomeline 
 High Dose 
 (N=35)  
Baseline 
  n                                   46 
  47 
  35 
  Mean (SD)                           25.1 (11.25) 
  25.2 (12.15) 
  21.8 (12.54) 
  Median (Range)                      23.5 (5;51) 
  21.0 (5;55) 
  18.0 (5;57) 
Week 24 
  n                                   46 
  47 
  35 
  Mean (SD)                           28.1 (13.70) 
  26.9 (12.09) 
  22.9 (12.84) 
  Median (Range)                      24.0 (8;59) 
  25.0 (8;62) 
  19.0 (4;62) 
Change from Baseline 
  n                                   46 
  47 
  35 
  Mean (SD)                            3.0 (5.57) 
   1.7 (5.54) 
   1.1 (4.77) 
  Median (Range)                       3.0 (-8;16) 
   2.0 (-11;17) 
   0.0 (-7;13) 
 
  p-value(Dose Response) [1][2]     
 
 
  0.094 
 
  p-value(Xan - Placebo) [1][3]     
 
   0.160 
   0.135 
   Diff of LS Means (SE)            
 
-1.6 (1.10) 
-1.8 (1.20) 
   95% CI                           
 
(-3.7;0.6) 
(-4.2;0.6) 
 
  p-value(Xan High - Xan Low) [1][3]
 
 
   0.843 
   Diff of LS Means (SE)            
 
 
-0.2 (1.21) 
   95% CI                           
 
 
(-2.6;2.2) 
 
